Amedeo Smart

Free Medical Literature Service


 

Amedeo

Head and Neck Cancer

  Free Subscription

Articles published in
Anticancer Res
    November 2024
  1. ESASHI R, Aoyama T, Maezawa Y, Hashimoto I, et al
    The Clinical Impact of the Systemic Immune-inflammation Index in Esophageal Cancer Patients Receiving Curative Treatment.
    Anticancer Res. 2024;44:5035-5041.
    >> Share

  2. MIYASAKA Y, Kusano Y, Mizoguchi N, Takayama Y, et al
    Development of a Tumor Growth-responsive Robust Planning Method for Head and Neck Cancer in Carbon-ion Radiotherapy.
    Anticancer Res. 2024;44:5113-5122.
    >> Share

    October 2024
  3. MIYAKE R, Takeyama H, Manome Y, Koyama M, et al
    Thyroid Cancer With Autocrine Sialyl-fibronectin Depletion Has a Poor Prognosis due to EMT Progression.
    Anticancer Res. 2024;44:4561-4568.
    >> Share

  4. NA YM, Park SC, An SY, Ma HU, et al
    Analysis of Initial Outcomes of Gas-insufflation One-step Single-port Transaxillary (GOSTA) Robotic Thyroidectomy for Thyroid Cancer.
    Anticancer Res. 2024;44:4585-4592.
    >> Share

  5. KUGA R, Hashimoto K, Yamamoto H, Taniguchi M, et al
    Clinicopathological Review of Head and Neck Squamous Cell Carcinomas After Neoadjuvant Chemotherapy.
    Anticancer Res. 2024;44:4593-4603.
    >> Share

  6. XU L, Tian A, Fan R, Lai J, et al
    Synchronous Pancreatic Ductal Adenocarcinoma and Nasopharyngeal Carcinoma With Associated Novel Pathogenic ATM Mutation.
    Anticancer Res. 2024;44:4605-4608.
    >> Share

    September 2024
  7. SATO M, Sato T, Hozumi C, Han Q, et al
    [(11)C]Methionine PET vs. [(18)F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients.
    Anticancer Res. 2024;44:3891-3898.
    >> Share

  8. HAGIWARA K, Matsuki T, Okada T, Fushimi C, et al
    Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.
    Anticancer Res. 2024;44:4057-4072.
    >> Share

  9. MATSUMURA S, Kaira K, Kuba K, Inoue H, et al
    Potential of Nutritional Markers as Predictors After Immunotherapy in Advanced Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:4049-4056.
    >> Share

  10. HIRAKAWA H, Ikegami T, Kinjyo H, Hayashi Y, et al
    Feasibility of Near-infrared Photoimmunotherapy Combined With Immune Checkpoint Inhibitor Therapy in Unresectable Head and Neck Cancer.
    Anticancer Res. 2024;44:3907-3912.
    >> Share

  11. FUJII S, Okamoto I, Okada T, Tokashiki K, et al
    Effect of Nivolumab on the Quality of Life in Recurrent/Metastatic Head and Neck Cancer.
    Anticancer Res. 2024;44:4085-4092.
    >> Share

  12. CHEN CH, Chin YT, Hsu SW, Shih LC, et al
    Impact of Matrix Metalloproteinase-8 Polymorphisms on Nasopharyngeal Carcinoma Risk.
    Anticancer Res. 2024;44:3813-3820.
    >> Share

  13. MATSUDA H, Iwahori K, Takeoka T, Kato R, et al
    Helicobacter pylori Infection Affects the Tumor Immune Microenvironment of Esophageal Cancer Patients.
    Anticancer Res. 2024;44:3799-3805.
    >> Share

    August 2024
  14. HIRASAWA Y, Kubota Y, Mura E, Suzuki R, et al
    Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment.
    Anticancer Res. 2024;44:3397-3407.
    >> Share

  15. RACINE F, Louandre C, Demagny J, Godin C, et al
    Transcriptional Induction of SERPINE1 and Fibrinolysis Inhibition as Predominant Effects of Glucocorticoids on the Cancer Coagulome.
    Anticancer Res. 2024;44:3269-3276.
    >> Share

  16. WU J, Chun C, Lagunas AM, Crowe DL, et al
    Lysine Methyltransferase 2D Regulates Immune Response and Metastasis in Head and Neck Cancer.
    Anticancer Res. 2024;44:3231-3242.
    >> Share

  17. HUBER L, Knuttel MT, Kramer B, Zaubitzer L, et al
    Influence of Tyrosine Kinase Inhibitors and Everolimus on TGFbeta1 and TGF-beta Receptor 2 in Squamous Cell Carcinoma Cells.
    Anticancer Res. 2024;44:3287-3294.
    >> Share

  18. GAO A, Kim DW, Pei M, Kim KY, et al
    Implications of TP-positive CAFs in the Bone Invasion of Oral Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:3365-3374.
    >> Share

    July 2024
  19. CHIKAMATSU K, Ida S, Masuda K, Horikawa M, et al
    Enhancement of Tumor Antigen-specific T-cell Responses by Immune Checkpoint Blockade in Human Papillomavirus-related Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2921-2931.
    >> Share

  20. TODA S, Saito N, Kadoya M, Okubo Y, et al
    Association of BRAF or TERT Promoter Mutations and Advanced Papillary Thyroid Carcinoma.
    Anticancer Res. 2024;44:3141-3147.
    >> Share

  21. GEISTHOFF UW, Droege F, Hand C, Holtmann LC, et al
    Clinical Value of Fine Needle Aspiration Cytology and Core Needle Biopsy in Head and Neck Pathology - A Nationwide Survey in Germany.
    Anticancer Res. 2024;44:3115-3124.
    >> Share

  22. SUZUKI G, Yamazaki H, Aibe N, Masui K, et al
    Optimizing Therapeutic Approaches in Superficial Esophageal Cancer: Reduced-volume Radiotherapy and Dose-dense Chemotherapy After Endoscopic Resection.
    Anticancer Res. 2024;44:3133-3139.
    >> Share

    June 2024
  23. KRUGER K, Grust A, Muallah D, Patenge A, et al
    PIK3CA Hotspot Mutations in Saliva as a Diagnostic Marker in Oral Squamous Cell Carcinoma Patients.
    Anticancer Res. 2024;44:2369-2376.
    >> Share

  24. TAI CH, Wang CC, Shih YC, Chen YJ, et al
    Functional Role of DUSP6 in the EGFR-mediated Progression of Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2545-2554.
    >> Share

  25. LIN CH, Chiang CC, Shih YC, Tung SL, et al
    Elucidating the Role of Let-7d-5p and OLR1 in the Progression and Prognosis of Oral Squamous Cell Carcinoma via FAK/P53 Signaling Axis.
    Anticancer Res. 2024;44:2517-2531.
    >> Share

  26. HUJANEN R, Salo T, Eklund KK, Salem A, et al
    Ex Vivo Evaluation of Antiangiogenic Drugs in Oral Cancer: Potential Implications for Targeting Vasculogenic Mimicry.
    Anticancer Res. 2024;44:2377-2392.
    >> Share

    May 2024
  27. LUKOCEVICIUTE M, Zupancic M, Kostopoulou ON, Holzhauser S, et al
    Curcumin Alone and Combined With PI3K Inhibitors Elicits Positive Effects on Oropharyngeal Cancer Cell Lines Regardless of HPV Status.
    Anticancer Res. 2024;44:1863-1876.
    >> Share

  28. ICHIKAWA H, Ishikawa T, Sugai M, Muneoka Y, et al
    Prognostic Significance of NQO1 Expression in Non-neoplastic Esophageal Squamous Epithelium for Patients With Esophageal Cancer.
    Anticancer Res. 2024;44:1915-1924.
    >> Share

  29. AOYAMA T, Hashimoto I, Maezawa Y, Hara K, et al
    The Prognostic Immune and Nutritional Indices Are Independent Prognostic Factors for Esophageal Cancer Patients Who Receive Curative Treatment.
    Anticancer Res. 2024;44:2185-2192.
    >> Share

  30. SAMUKAWA Y, Ouchi Y, Miyashita T, Rahman A, et al
    Systemically Administered D-allose Inhibits the Tumor Energy Pathway and Exerts Synergistic Effects With Radiation.
    Anticancer Res. 2024;44:1895-1903.
    >> Share

    April 2024
  31. KIM SI, Lee JW, Eun YG, Lee YC, et al
    Utilizing the AJCC 8(th) Staging to Discriminate Survival Outcomes in HPV-associated Oropharyngeal Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:1703-1710.
    >> Share

  32. TANAKA Y, Sato Y, Horaguchi T, Fujibayashi S, et al
    Radiomics Features Using Dual-energy CT for Lymph Nodes After Preoperative Chemotherapy for Esophageal Cancer.
    Anticancer Res. 2024;44:1661-1674.
    >> Share

  33. ZUPANCIC M, Nasman A, Friesland S, Dalianis T, et al
    Adenoid Cystic Carcinoma, Clinical Presentation, Current Treatment and Approaches Towards Novel Therapies.
    Anticancer Res. 2024;44:1325-1334.
    >> Share

  34. NOH MH, Kim HY, Kim DH, Moon SH, et al
    Role of Peroxiredoxin 1 Induced by Epstein-Barr Virus Infection in Nasopharyngeal Carcinoma.
    Anticancer Res. 2024;44:1425-1440.
    >> Share

  35. YAMAGUCHI T, Okamoto K, Saito H, Shimada M, et al
    Impact of Arteriosclerosis on Reconstruction-related Complications After Esophagectomy and Usefulness of Tailor-made Reconstruction Technique.
    Anticancer Res. 2024;44:1719-1726.
    >> Share

    March 2024
  36. KODAMA H, Kadowaki S, Nakazawa T, Matsubara Y, et al
    Safety and Efficacy of Gemcitabine Plus Cisplatin Against Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective Study.
    Anticancer Res. 2024;44:1227-1232.
    >> Share

  37. EDEN D, Ghose A, Moschetta M, Perez-Fidalgo JA, et al
    Immunotherapy Combined With Standard Therapies in Head and Neck Squamous Cell Carcinoma - A Meta-analysis.
    Anticancer Res. 2024;44:861-878.
    >> Share

  38. SOHDA M, Hara K, Kuriyama K, Tateno K, et al
    Effectiveness of Combination Chemotherapy With Docetaxel, Nedaplatin, and 5-Fluorouracil for Advanced and Recurrent Esophageal Cancer.
    Anticancer Res. 2024;44:1309-1315.
    >> Share

  39. BAUDREXL J, Sakkas A, Pietzka S, Derka S, et al
    Evaluation of Five-year Overall Survival Rates Among 18,331 Head and Neck Cancer Patients Exposed to Different Targeted Therapies Through Real-world Data in a Case-controlled Study.
    Anticancer Res. 2024;44:1247-1270.
    >> Share

  40. CHEN PH, Lu HK, Renn TY, Chang TM, et al
    Plumbagin Induces Reactive Oxygen Species and Endoplasmic Reticulum Stress-related Cell Apoptosis in Human Oral Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:1173-1182.
    >> Share

  41. MACHIDA T, Sakuma K, Fuwa N, Tanaka A, et al
    Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:993-1002.
    >> Share

    February 2024
  42. AOYAMA T, Hashimoto I, Maezawa Y, Hara K, et al
    CRP-albumin-lymphocyte (CALLY) Index Is an Independent Prognostic Factor for the Esophageal Cancer Patients Who Received Curative Treatment.
    Anticancer Res. 2024;44:815-822.
    >> Share

  43. ZOU X, Lin Y, Ren H, Meng Y, et al
    PRMT5-PAK1 Signaling Participates in Metastasis and Is Associated With Poor Prognosis in Human Esophageal Carcinoma.
    Anticancer Res. 2024;44:593-604.
    >> Share

  44. HERAMB-AAMOT J, Mala T, Fauske L
    Everyday Life Six to Eight Months After Esophagectomy for Cancer: A Qualitative Study.
    Anticancer Res. 2024;44:743-750.
    >> Share

    January 2024
  45. AOYAMA T, Kato A, Maezawa Y, Hashimoto I, et al
    Lymphocyte to Monocyte Ratio Is an Independent Prognostic Factor in Patients With Esophageal Cancer Who Receive Curative Treatment.
    Anticancer Res. 2024;44:339-346.
    >> Share

  46. BAUDREXL J, Pietzka S, Scheurer M, Schramm A, et al
    Sex-specific Real-World 5-year Overall Survival Rates for (Radio)chemotherapy, Targeted Therapy, and Combinations in Patients With Head and Neck Cancer.
    Anticancer Res. 2024;44:267-286.
    >> Share

  47. LEE S, Fujiwara Y, Gyobu K, Tamura T, et al
    Evaluation of Intraoperative Neural Monitoring During Thoracoscopic Surgery for Esophageal Cancer.
    Anticancer Res. 2024;44:157-166.
    >> Share

  48. AOYAMA T, Kato A, Hashimoto I, Maezawa Y, et al
    Pretreatment Fibrinogen Level Is a Prognostic Factor for Esophageal Cancer Patients Who Receive Curative Treatment.
    Anticancer Res. 2024;44:249-255.
    >> Share

  49. KATO A, Aoyama T, Maezawa Y, Hashimoto I, et al
    Geriatric Nutritional Risk Index Is an Independent Prognostic Factor for Patients With Esophageal Cancer Who Receive Curative Treatment.
    Anticancer Res. 2024;44:331-337.
    >> Share

  50. TSUCHIDA K, Shiga K, Katagiri K, Saito D, et al
    Increasing Patients With HPV-positive Oropharyngeal Squamous Cell Carcinoma and its Oncologic Outcomes in the Rural Region in Northern Japan.
    Anticancer Res. 2024;44:403-407.
    >> Share

  51. YOSHIMURA N, Fujiwara M, Igeta M, Suzuki H, et al
    Risk Factors Causing Hypothyroidism in Patients With Head and Neck Cancer After Radiotherapy Using SIB-VMAT.
    Anticancer Res. 2024;44:323-329.
    >> Share

  52. SUGASE T, Kanemura T, Takeoka T, Matsuura N, et al
    Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:185-193.
    >> Share

  53. EBELING M, Derka S, Baudrexl J, Sakkas A, et al
    Ibuprofen Reduces 5-Year Overall Survival of Head and Neck Cancer Patients With Immunotherapy - A Retrospective Case-controlled Real-World Data Analysis of 10,000 Patients.
    Anticancer Res. 2024;44:313-322.
    >> Share

    December 2023
  54. ASANUMA K, Ishihara M, Nakamura T, Uchida K, et al
    Histological Assessment of Synovial Sarcoma Before and After TCR-T Cell Therapy and Cryoablation: A Case Report.
    Anticancer Res. 2023;43:5737-5748.
    >> Share

  55. SUZUKI H, Haimoto S, Inaba Y, Tachibana H, et al
    Peptide Receptor Radionuclide Therapy for Recurrent Olfactory Neuroblastoma After Cranioplasty for Surgical Infection: A Case Report.
    Anticancer Res. 2023;43:5723-5728.
    >> Share

  56. SAMARA W, Moztarzadeh O, Pernicky J, Baghalipour N, et al
    Carotid Artery Stenosis on Panoramic Radiographs and CT Scans in Patients With Malignancies After Radiotherapy.
    Anticancer Res. 2023;43:5657-5662.
    >> Share

  57. IDEL C, Ribbat-Idel J, VON Bernuth A, Fleckner J, et al
    Correlation of Intra-tumoral and Peripheral PD-1/PD-L1 Immunity in Head and Neck Cancer.
    Anticancer Res. 2023;43:5349-5358.
    >> Share

  58. BURYSKA S, Patel K, Wuertz B, Gaffney PM, et al
    Potential Roles of Activin in Head and Neck Squamous Cell Carcinoma Progression and Mortality.
    Anticancer Res. 2023;43:5299-5310.
    >> Share

    November 2023
  59. HSU CC, Wu YT, Yu SJ, Chen PJ, et al
    NAD(P)H:quinone Oxidoreductase 1 Is Involved in AZ-1-induced Apoptotic Effects in Nasopharyngeal Carcinoma TW01 Cells.
    Anticancer Res. 2023;43:4879-4885.
    >> Share

  60. WATANABE H, Kano K, Hashimoto I, Tanabe M, et al
    Intraoperative Blood Loss Impacts Recurrence and Survival in Patients With Locally Advanced Esophageal Cancer.
    Anticancer Res. 2023;43:5173-5179.
    >> Share

  61. NATSUKI S, Miki Y, Tanaka H, Nishiyama M, et al
    Usefulness of Biopsy Specimens for Evaluating CD103(+) Tumor-resident Memory T Cells in Esophageal Cancer.
    Anticancer Res. 2023;43:4823-4832.
    >> Share

  62. FUKUSHIMA H, Naruse T, Furukawa K, Omori K, et al
    Extranodal Extension and Epithelial Cell Adhesion Molecule Over-expression in Oral Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:5155-5166.
    >> Share

  63. CHEN H, Pei M, Shin SW, Moon S, et al
    Implication of TIPE2 Expression on the Malignant Transformation of Oral Leukoplakia.
    Anticancer Res. 2023;43:4937-4946.
    >> Share

  64. ISHIDA Y, Shintani T, Nobumoto T, Sakurai S, et al
    Interaction of Integrin alphavbeta8 With Type I Collagen Promotes Squamous Cell Carcinoma Cell Motility via RAC1 Activation.
    Anticancer Res. 2023;43:4833-4841.
    >> Share

  65. KOWKABANY G, Jimenez PB, Sharan S, Bansal S, et al
    Inequities in Time to Treat Thyroid Cancer.
    Anticancer Res. 2023;43:5025-5030.
    >> Share

  66. KANEMOTO H, Obata K, Umemori K, Hasegawa K, et al
    Multimodal Prediction of Cervical Lymph Node Metastasis and Recurrence in Oral Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:4993-5001.
    >> Share

  67. ASAKA S, Shimakawa T, Nishiguchi R, Yamaguchi K, et al
    Preoperative and Postoperative C-Reactive Protein to Albumin Ratio (CAR) as a Prognostic Marker for Survival of Esophageal Squamous Cell Carcinoma Patients After Surgery.
    Anticancer Res. 2023;43:5139-5147.
    >> Share

    October 2023
  68. ZHOU J, Liu J, Zhang KE, Lv J, et al
    High-throughput Sequencing Analysis of Differentially Expressed microRNAs Associated With SREBP1 in Differentiated Thyroid Carcinoma.
    Anticancer Res. 2023;43:4435-4446.
    >> Share

  69. DURZYNSKA M, Dos Santos FLC, Michalek IM
    Clinicopathological Characteristics, Survival Outcomes, and Prognostic Factors in Adult Patients With Sinonasal Rhabdomyosarcoma: Insights from a Retrospective Cohort Study.
    Anticancer Res. 2023;43:4517-4524.
    >> Share

  70. DURZYNSKA M, Dos Santos FLC, Matuszczyk A, Derezinska-Wolek E, et al
    Prognostic Implications of PRAME Expression and Clinicopathological Factors in Sinonasal Mucosal Melanoma: A Single-center Cohort Study of 30 Cases.
    Anticancer Res. 2023;43:4551-4557.
    >> Share

  71. TAKEHARA Y, Tamaki T, Mimura K, Saito K, et al
    Immunological Responses Associated With Neoadjuvant Therapy in the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:4691-4700.
    >> Share

  72. DUMITRU CS, Raica M
    Vascular Endothelial Growth Factor Family and Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:4315-4326.
    >> Share

    September 2023
  73. SAKURAI K, Ando T, Ideta Y, Hayashi Y, et al
    Transcriptome of Oral Cancer Cells Adapted to Suspension Culture Is Potentially Related to Cancer Progressive Phenotypes.
    Anticancer Res. 2023;43:3905-3911.
    >> Share

  74. RADES D, Delikanli C, Yu NY, Janssen S, et al
    Development of Distress During a Radiotherapy Course for Head-and-neck Cancer.
    Anticancer Res. 2023;43:4149-4153.
    >> Share

  75. VIRGILIO E, Bonfili D, Bettoni S, Vona L, et al
    Tonsillectomy as Prevention of Tonsil and Base of Tongue Cancer: Systematic Review and Meta-analysis on the Immuno-Oncological Effect of One Among the Most Common Surgeries in the World.
    Anticancer Res. 2023;43:3881-3889.
    >> Share

  76. HSU LC, Lin CN, Hsu FT, Chen YT, et al
    Imipramine Suppresses Tumor Growth and Induces Apoptosis in Oral Squamous Cell Carcinoma: Targeting Multiple Processes and Signaling Pathways.
    Anticancer Res. 2023;43:3987-3996.
    >> Share

  77. YANG CH, Chang YC, Hsu CC, Lin CH, et al
    Fucoidan Enhances Cisplatin-induced Effects on SCC-25 Human Oral Cancer Cells by Inhibiting the PI3K/AKT Pathway.
    Anticancer Res. 2023;43:4015-4022.
    >> Share

  78. SUGASE T, Kanemura T, Takeoka T, Urakawa S, et al
    Clinical Impact of Enhanced Recovery After Esophagectomy in Patients With Esophageal Cancer.
    Anticancer Res. 2023;43:4197-4205.
    >> Share

    August 2023
  79. YAMASHITA G, Okamoto I, Ito T, Tokashiki K, et al
    Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:3679-3683.
    >> Share

  80. ISHINAGA H, Yasuma T, D'Alessandro-Gabazza CN, D'Alessandro VF, et al
    Intravenous Delivery of miR-21 Inhibitor in Mice With Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:3487-3491.
    >> Share

  81. DEN BOER R, Fourie L, Weusten B, Moons L, et al
    Challenges During Esophagectomy in Presence of Thoracic Anatomical Anomalies: A Report of Three Cases.
    Anticancer Res. 2023;43:3553-3561.
    >> Share

  82. TAGAWA Y, Sakagami H, Tanuma SI, Amano S, et al
    Potentiation of Anticancer Activity of G(2)/M Blockers by Mild Hyperthermia.
    Anticancer Res. 2023;43:3429-3439.
    >> Share

    July 2023
  83. HIRANO K, Hirohata R, Hamai Y, Yamaguchi S, et al
    Esophageal Neuroendocrine Carcinoma With Pathological Complete Response After Neoadjuvant Chemotherapy Followed by Robot-assisted Surgery: A Case Report.
    Anticancer Res. 2023;43:3289-3293.
    >> Share

  84. SEO Y, Lee J, Kim J, Shim S, et al
    FOXJ3 Regulates Cell Proliferation and Motility Through Modulating Snail Expression in Breast Cancer Cells.
    Anticancer Res. 2023;43:2995-3001.
    >> Share

  85. DAVAKIS S, Kapelouzou A, Sakellariou S, Kyriakoulis KG, et al
    Clinical and Oncological Impact of the Toll-like Receptor-3 and -4 in Esophageal and Gastro-esophageal Junction Adenocarcinoma.
    Anticancer Res. 2023;43:3183-3191.
    >> Share

  86. WOLL E, Amann A, Eisterer W, Gerger A, et al
    Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy - An Update.
    Anticancer Res. 2023;43:2889-2897.
    >> Share

  87. SUZUKI H, Sasaki E, Tamaki T, Kodaira T, et al
    Association Between 18F-Fluorodeoxyglucose Uptake and Mutation Status of Epidermal Growth Factor Receptor in Sinonasal Tract Cancer.
    Anticancer Res. 2023;43:3247-3253.
    >> Share

    June 2023
  88. ITO S, Ohgaki K, Kawazoe T, Wang H, et al
    Successful Treatment of Refractory Enterocutaneous Fistula After Esophagectomy Using Soft Coagulation by an Endoscopic and Percutaneous Approach: A Case Report.
    Anticancer Res. 2023;43:2873-2877.
    >> Share

  89. NAGASAWA S, Oshima T, Hara K, Nakazono M, et al
    Clinical Significance of Pre-treatment Circumferential Tumor Location in Patients With cStage IB-III Esophageal Squamous Cell Cancer.
    Anticancer Res. 2023;43:2697-2705.
    >> Share

  90. CELIK E, Baues C, Trommer M, Fan J, et al
    Dose-dependent Effects of Unintended Splenic Irradiation After Neoadjuvant Radiochemotherapy for Esophageal Cancer.
    Anticancer Res. 2023;43:2733-2739.
    >> Share

  91. WU YT, Hsu CC, Huang BM, Chang YC, et al
    Serum Starvation Induces Matrix Metalloproteinase 9 Expression in Nasopharyngeal Carcinoma Cells Through the ERK-AP1 Pathway In Vitro.
    Anticancer Res. 2023;43:2583-2591.
    >> Share

  92. KONISHI K, Kamiya M, Ohira K, Hirata M, et al
    Impact of Radiation Dose on Treatment of Maxillary Cancer With Superselective Intra-arterial Cisplatin With Radiotherapy.
    Anticancer Res. 2023;43:2859-2864.
    >> Share

  93. CHANG TS, Lin JJ, Cheng KC, Su JH, et al
    11-epi-Sinulariolide Acetate-induced Apoptosis in Oral Cancer Cells Is Regulated by FOXO Through Inhibition of PI3K/AKT Pathway.
    Anticancer Res. 2023;43:2625-2634.
    >> Share

  94. OKADA T, Fushimi C, Matsuki T, Tokashiki K, et al
    Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study.
    Anticancer Res. 2023;43:2717-2724.
    >> Share

  95. SAITO Y, Takahashi T, Hiramatsu K, Serada S, et al
    Nano-particulate Toll-like Receptor 9 Agonist Potentiates the Antitumor Activity of Anti-Glypican-1 Antibody.
    Anticancer Res. 2023;43:2425-2432.
    >> Share

  96. SATO K, Sano D, Takahashi H, Kuwahara T, et al
    P4HA1 Promotes Cell Migration and Colonization in Hypopharyngeal Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:2571-2582.
    >> Share

  97. SHIGENAGA D, Ichiro O, Watanabe S, Hata M, et al
    Toxic Effects of Volume-modulated Arc Therapy for Esophageal Squamous Cell Cancer: Preliminary Clinical Results.
    Anticancer Res. 2023;43:2791-2798.
    >> Share

  98. CHARALABOPOULOS A, Davakis S, Sakarellos P, Mpaili E, et al
    Impact of Minimally Invasive Intrathoracic Hand-sewn Esophago-gastric Anastomosis in Esophagectomy for Cancer.
    Anticancer Res. 2023;43:2749-2755.
    >> Share

    May 2023
  99. KONISHI M, Hirokawa J, Miyoshi S, Katsuta T, et al
    Effectiveness of Spacers in Brachytherapy With (198)Au Grains for Patients With Buccal Mucosa Cancer.
    Anticancer Res. 2023;43:2265-2271.
    >> Share

  100. AL-SALOOL A, Soror T, Yu NY, Idel C, et al
    Emotional Distress in Head-and-neck Cancer Patients Scheduled for Chemoradiation or Radiotherapy Alone.
    Anticancer Res. 2023;43:2227-2233.
    >> Share

  101. KUROGOCHI T, Matsumoto A, Nyumura Y, Tanishima Y, et al
    Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer.
    Anticancer Res. 2023;43:2293-2298.
    >> Share

    April 2023
  102. GANESH D, Dafar A, Niklasson J, Sandberg I, et al
    EZH2 Expression Correlates With T-Cell Infiltration in Oral Leukoplakia and Predicts Cancer Transformation.
    Anticancer Res. 2023;43:1533-1542.
    >> Share

  103. COFRE A, Walter S, Buentzel J, Hubner J, et al
    Malnutrition in Head and Neck Cancer: A Patient-reported Outcome Study.
    Anticancer Res. 2023;43:1663-1673.
    >> Share

  104. HIROTAKI K, Tomizawa K, Moriya S, Ito M, et al
    Impact of Anatomical Position Errors on Dose Distribution in Head and Neck Radiotherapy and Robust Image Registration Against Anatomical Changes.
    Anticancer Res. 2023;43:1827-1834.
    >> Share

  105. IWASHITA K, Kubota H, Nishioka R, Emoto Y, et al
    Prognostic Value of Radiomics Analysis of Skeletal Muscle After Radical Irradiation of Esophageal Cancer.
    Anticancer Res. 2023;43:1749-1760.
    >> Share

  106. PANTAZOPOULOS T, Leventakou D, Koufopoulos N, Pouliakis A, et al
    Significance of MYB and NTRK Expression in Head and Neck Adenoid Cystic Carcinoma.
    Anticancer Res. 2023;43:1709-1717.
    >> Share

  107. AUGUSTIN Y, Zaidi S, Jones RL, Benson C, et al
    Biphenotypic Sinonasal Sarcoma: Case Reports of Diagnostic Findings and Clinical Management of 3 Cases.
    Anticancer Res. 2023;43:1581-1589.
    >> Share

  108. LANDSTROM F, Sandberg J, Reizenstein J
    Life-threatening Airway Complication After Radioactive Iodine Treatment: A Case Report and Review of the Literature.
    Anticancer Res. 2023;43:1853-1855.
    >> Share

  109. MACIA-RIVAS L, Fernandez-Laguna CL, Alvarez-Asteinza C, Maray I, et al
    Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs. Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population.
    Anticancer Res. 2023;43:1681-1688.
    >> Share

    March 2023
  110. NAKAYAMA H, Saito N, Kasajima R, Suganuma N, et al
    Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
    Anticancer Res. 2023;43:1073-1077.
    >> Share

  111. LIN HC, Wang CC, Wu CF, Lin YH, et al
    Hinokitiol Inhibits the Viability of Oral Squamous Carcinoma Cells by Inducing Apoptosis and Autophagy.
    Anticancer Res. 2023;43:1167-1173.
    >> Share

  112. SHIMIZU D, Miyata K, Fukaya M, Sugita S, et al
    Risk Factors for Muscle Loss During Neoadjuvant Therapy for Esophageal Cancer.
    Anticancer Res. 2023;43:1309-1315.
    >> Share

  113. WAGNER SM, Magnes T, Melchardt T, Kiem D, et al
    Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer.
    Anticancer Res. 2023;43:1273-1282.
    >> Share

  114. HOELL PA, Elsayad K, Berssenbruegge H, Hering D, et al
    Efficacy of Multimodality Approach in Patients With Recurrent Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:1255-1263.
    >> Share

    February 2023
  115. RADES D, Zwaan I, Janssen S, Yu NY, et al
    Evaluation of the Impact of Smoking and Alcohol Consumption on Toxicity and Outcomes of Chemoradiation for Head and Neck Cancer.
    Anticancer Res. 2023;43:823-830.
    >> Share

  116. HAN SH, O'Toole TR, Meyer RG, Geiersbach KB, et al
    Clear-cell Variant of Mucoepidermoid Carcinoma Presenting as a Palatal Mass in a 10-Year-old Boy.
    Anticancer Res. 2023;43:939-942.
    >> Share

  117. ZWAAN I, Soror T, Bruchhage KL, Hakim SG, et al
    Comparison of Two Cisplatin Regimens for Chemoradiation in Patients With Squamous-cell Carcinoma of the Head and Neck.
    Anticancer Res. 2023;43:795-800.
    >> Share

  118. CIERPIKOWSKI P, Lis-Nawara A, Bar J
    Prognostic Value of WNT1, NOTCH1, PDGFRbeta, and CXCR4 in Oral Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:591-602.
    >> Share

    January 2023
  119. FUKUDA T, Baba H, Okumura T, Kanda M, et al
    miR-877-3p as a Potential Tumour Suppressor of Oesophageal Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:35-43.
    >> Share

  120. IJAZ K, Yin F
    Papillary Thyroid Carcinoma With Squamous Dedifferentiation: A Potential Diagnostic Pitfall.
    Anticancer Res. 2023;43:255-258.
    >> Share

  121. MATSUO M, Baba S, Hashimoto K, Isoda T, et al
    Utility of FDG PET at the Initial Radioiodine Therapy in Differentiated Thyroid Cancer.
    Anticancer Res. 2023;43:183-190.
    >> Share

    December 2022
  122. KUSAKA T, Shiga K, Katagiri K, Saito D, et al
    Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
    Anticancer Res. 2022;42:6047-6056.
    >> Share

  123. INAGAKI T, Sato M, Kin M, Otsuka K, et al
    Predictive Factors of Febrile Neutropenia After Primary Prophylactic Pegfilgrastim With DCF Chemotherapy for Esophageal Cancer.
    Anticancer Res. 2022;42:6071-6081.
    >> Share

  124. HAMAI Y, Emi M, Ibuki Y, Kurokawa T, et al
    Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
    Anticancer Res. 2022;42:6037-6045.
    >> Share

  125. KOUZU K, Tsujimoto H, Uehata N, Ishibashi Y, et al
    Modified Geriatric Nutrition Risk Index as a Prognostic Predictor for Unresectable/Recurrent Esophageal Cancer.
    Anticancer Res. 2022;42:5999-6006.
    >> Share

  126. MORISHITA Y, Takenouchi K, Sakashita S, Matsuura K, et al
    Immunohistochemical Analysis of Common Cancer Antigens in Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:5751-5761.
    >> Share

  127. MOTOYAMA S, Hosaka M, Kamei T, Ueno M, et al
    A Multi-institutional Study to Diagnose the Risk of Lymph Node Metastasis Using a CRP Genetic Polymorphism Test Kit in pT1, cN0 Thoracic Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:6105-6112.
    >> Share

  128. DE FELICE F, Musio D, Serpone M, Vavalle G, et al
    Simultaneously Integrated Boost Affects Survival in Locally Advanced p16-Negative Oropharyngeal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:5909-5915.
    >> Share

  129. TAN JY, Adeoye J, Thomson P, Sharma D, et al
    Predicting Overall Survival Using Machine Learning Algorithms in Oral Cavity Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:5859-5866.
    >> Share

    November 2022
  130. KING K, Rauch R, Roy S, Menyok O, et al
    Impact of Routine Surveillance Imaging on Recurrence in Sinonasal Malignancies.
    Anticancer Res. 2022;42:5449-5455.
    >> Share

  131. AOYAMA T, Maezawa Y, Hara K, Ju M, et al
    The Clinical Impact of Other Primary Cancer in Patients Who Received Curative Treatment for Esophageal Cancer.
    Anticancer Res. 2022;42:5635-5641.
    >> Share

  132. SATO H, Nishikawa K, Hamakawa T, Kusunoki C, et al
    Evaluating Neoadjuvant Chemotherapy for Lower Esophageal Squamous Cell Carcinoma by Measuring Esophageal Wall Thickness.
    Anticancer Res. 2022;42:5655-5662.
    >> Share

  133. CHO JS, Kim HK
    Thyroglobulin Levels as a Predictor of Papillary Cancer Recurrence After Thyroid Lobectomy.
    Anticancer Res. 2022;42:5619-5627.
    >> Share

  134. REUTER I, Muller HH, Wiegand S
    Prognostic Significance of the Nodal Ratio and Number of Positive Nodes in Patients With Squamous Cell Carcinomas of the Head and Neck.
    Anticancer Res. 2022;42:5567-5570.
    >> Share

  135. KYLMA AK, Sorsa T, Jouhi L, Mustonen HK, et al
    Prognostic Role of Porphyromonas gingivalis Gingipain Rgp and Matrix Metalloproteinase 9 in Oropharyngeal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:5415-5430.
    >> Share

  136. SU PH, Hsu CC, Hsueh SW, Hung CY, et al
    Potential Utility of the Mallampati Score for Prediction of Treatment Compliance and Safety Profiles of Patients With Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiotherapy.
    Anticancer Res. 2022;42:5609-5618.
    >> Share

  137. LANDSTROM F, Reizenstein J, Kristiansson S
    Detection of Recurrence After Primary Treatment for Oropharyngeal Carcinoma.
    Anticancer Res. 2022;42:5597-5600.
    >> Share

    October 2022
  138. OKADA T, Matsuki T, Fushimi C, Okamoto I, et al
    Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:4907-4912.
    >> Share

  139. SAKAI M, Sohda M, Uchida S, Yamaguchi A, et al
    Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-RT) for Patients With Potentially Resectable Esophageal Cancer.
    Anticancer Res. 2022;42:4929-4935.
    >> Share

    September 2022
  140. MILAS ZL, Neelands B, Trufan SJ, Benbow J, et al
    Survivorship Care Plans Improve the Identification of Post-radiation Hypothyroidism After Head and Neck Cancer Treatment.
    Anticancer Res. 2022;42:4429-4437.
    >> Share

  141. SANO D, Tokuhisa M, Takahashi H, Hatano T, et al
    Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan.
    Anticancer Res. 2022;42:4477-4484.
    >> Share

  142. TSUZUKI H, Suzuki H, Tamaki T, Sone M, et al
    Detection Ability of (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Clinical T Classification of Synchronous Esophageal Cancer in Pharyngeal Cancer.
    Anticancer Res. 2022;42:4597-4602.
    >> Share

  143. RADES D, Kopelke S, Schild SE, Tvilsted S, et al
    Sleep Problems Prior to Radio-chemotherapy in Patients With Locally Advanced Cancer of the Esophagus or the Esophagogastric Junction.
    Anticancer Res. 2022;42:4529-4533.
    >> Share

  144. YODA M, Sakuma K, Kii T, Tanaka A, et al
    Study of the Acquisition of Sensitivity to Paclitaxel Plus Cetuximab by the Addition of Low-dose Proteasome Inhibitor.
    Anticancer Res. 2022;42:4273-4283.
    >> Share

  145. YASUI K, Kondou R, Miyata H, Iizuka A, et al
    Immunological and Genetic Characterization of Patients With Head and Neck Cancer who Developed Recurrence.
    Anticancer Res. 2022;42:4417-4428.
    >> Share

  146. SAKUMA K, Kii T, Takahashi H, Suzuki S, et al
    An In Vivo Study of Local Administration of Low-dose Anti-PD-1 Antibody Using an Oral Cancer Cell Line.
    Anticancer Res. 2022;42:4293-4303.
    >> Share

  147. PAN SH, Chien WC, He JL, Shih LC, et al
    The Contribution of Flap Endonuclease 1 Genotypes to Oral Cancer Risk.
    Anticancer Res. 2022;42:4329-4335.
    >> Share

    August 2022
  148. SASAKI K, Tsuruda Y, Shimonosono M, Noda M, et al
    Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:3905-3911.
    >> Share

  149. SHIMONOSONO M, Sasaki K, Tsuruda Y, Noda M, et al
    Clinical Outcome After Esophagectomy or Definitive Chemoradiotherapy in Elderly Patients (>/=80 Years) With Esophageal Cancer.
    Anticancer Res. 2022;42:3953-3961.
    >> Share

  150. SMILE TD, Reddy CA, Matia B, Fleming CW, et al
    A Reappraisal of Definitive Chemoradiotherapy for Older Adults With Advanced Head and Neck Cancer.
    Anticancer Res. 2022;42:3845-3852.
    >> Share

  151. YOSHII H, Sekihara K, Ideta Y, Nakajima S, et al
    The Expression of SIRT6 Is Associated With Treatment Outcome in Elder Patients With Oral Cancer.
    Anticancer Res. 2022;42:3815-3823.
    >> Share

  152. FANG F, Zhang QI, Pinto-Cuberos JM, Lai J, et al
    Metastatic SMARCB1 Deficient Skin Carcinoma With Neuroendocrine Differentiation in the Parotid Glands Clinically Mimicking Primary Salivary Gland Malignancy: Unusual Case With Diagnostic Pitfalls.
    Anticancer Res. 2022;42:3971-3974.
    >> Share

    July 2022
  153. RADES D, Warwas B, Cremers F, Gerull K, et al
    Impact of Dose-Volume Parameters of Parotid Glands on Xerostomia in Patients Irradiated for Head-and-Neck Cancer.
    Anticancer Res. 2022;42:3551-3556.
    >> Share

  154. KAJIYAMA T, Serada S, Fujimoto M, Ohkawara T, et al
    SOCS1 Gene Therapy for Head and Neck Cancers: An Experimental Study.
    Anticancer Res. 2022;42:3361-3372.
    >> Share

  155. CHEN YK, Ngoc NTM, Chang HW, Su YF, et al
    Chlorogenic Acid Inhibition of Esophageal Squamous Cell Carcinoma Metastasis via EGFR/p-Akt/Snail Signaling Pathways.
    Anticancer Res. 2022;42:3389-3402.
    >> Share

  156. HUBER L, Birk R, Knuettel M, Rotter N, et al
    Targeted Treatment of HPV16-positive and -negative SCC Cells With Small Molecule Tyrosine Kinase Inhibitors and Everolimus Affects MMP2 and MMP14 Expression.
    Anticancer Res. 2022;42:3403-3411.
    >> Share

  157. PRATHAPHAN P, Reamtong O, Ngaokrajang U, Janvilisri T, et al
    Comparative Proteomic Profiling of Cisplatin-resistant Nasopharyngeal Carcinoma Cell Lines: Novel Biomarkers for Improving Chemotherapy of NPC.
    Anticancer Res. 2022;42:3507-3522.
    >> Share

  158. NAKAJIMA M, Muroi H, Kikuchi M, Kubo T, et al
    Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil.
    Anticancer Res. 2022;42:3725-3733.
    >> Share

  159. NAKANO T, Yasumatsu R, Hashimoto K, Kuga R, et al
    Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study.
    Anticancer Res. 2022;42:3653-3664.
    >> Share

  160. WEIDLE UH, Nopora A
    Long Non-coding RNAs Sponging MicroRNAs With Efficacy in Preclinical In Vivo Models of Esophageal Squamous Cell Cancer.
    Anticancer Res. 2022;42:3233-3249.
    >> Share

    June 2022
  161. DAVAKIS S, Kapelouzou A, Liakakos T, Mpoura M, et al
    The Role of Toll-like Receptors in Esophageal Cancer.
    Anticancer Res. 2022;42:2813-2818.
    >> Share

  162. TAKAHASHI K, Nishikawa K, Tanishima Y, Ishikawa Y, et al
    Risk Stratification of Postoperative Pneumonia in Patients Undergoing Subtotal Esophagectomy for Esophageal Cancer.
    Anticancer Res. 2022;42:3023-3028.
    >> Share

  163. BOOKA E, Kikuchi H, Haneda R, Soneda W, et al
    Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer.
    Anticancer Res. 2022;42:2977-2987.
    >> Share

  164. RADES D, Warwas B, Cremers F, Gerull K, et al
    The First Prognostic Tool to Estimate the Risk of Late Grade >/=3 Xerostomia in Patients Irradiated for Head-and-Neck Cancer.
    Anticancer Res. 2022;42:3035-3039.
    >> Share

  165. ITO K, Ishida H, Fujishima F, Nakamura Y, et al
    Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:2875-2882.
    >> Share

  166. MATSUKI T, Fushimi C, Miyamoto S, Takahashi H, et al
    Preoperative S-1 Therapy for Head and Neck Carcinoma During the Waiting Period Before Surgery.
    Anticancer Res. 2022;42:3177-3183.
    >> Share

  167. MUSIO D, DE Vincentiis M, D'Urso P, Musacchio A, et al
    Hearing Loss After Cisplatin-based Chemoradiotherapy for Locally Advanced Head and Neck Cancer: A Prospective Single-institution Study.
    Anticancer Res. 2022;42:3003-3009.
    >> Share

  168. ENDO M, Nishioka T, Numazaki K, Hasegawa H, et al
    Reactivation of p53 by RITA Induces Apoptosis in Human Oral Squamous Cell Carcinoma Cells.
    Anticancer Res. 2022;42:2931-2937.
    >> Share

    May 2022
  169. SUOJANEN J, Kainulainen S, Tarvainen L, Tornwall J, et al
    Handgrip Strength Predicts Poorly the Surgical Outcome or Length of Hospitalization in Patients With Surgically Operated Oral Cancer.
    Anticancer Res. 2022;42:2771-2774.
    >> Share

  170. OKAMOTO K, Ninomiya I, Saito H, Shimada M, et al
    Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study.
    Anticancer Res. 2022;42:2783-2790.
    >> Share

  171. EMI M, Hmai Y, Yoshikawa T, Hirohata R, et al
    Clinical Outcomes of Esophagectomy and Chemoradiotherapy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:2791-2795.
    >> Share

  172. KUNTE S, Sharett J, Wei W, Nasr C, et al
    Poorly Differentiated Thyroid Carcinoma: Single Institution Series of Outcomes.
    Anticancer Res. 2022;42:2531-2539.
    >> Share

  173. WARWAS B, Cremers F, Gerull K, Leichtle A, et al
    Risk Factors for Xerostomia Following Radiotherapy of Head-and-Neck Cancers.
    Anticancer Res. 2022;42:2657-2663.
    >> Share

  174. KATO T, Oshikiri T, Goto H, Sawada R, et al
    Impact of the Platelet-to-Lymphocyte Ratio as a Biomarker for Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:2775-2782.
    >> Share

  175. ACHILLA C, Papavramidis T, Angelis L, Chatzikyriakidou A, et al
    The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer.
    Anticancer Res. 2022;42:2261-2276.
    >> Share

  176. DOLL C, Steffen C, Beck-Broichsitter B, Richter M, et al
    The Prognostic Significance of p16 and its Role as a Surrogate Marker for Human Papilloma Virus in Oral Squamous Cell Carcinoma: An Analysis of 281 Cases.
    Anticancer Res. 2022;42:2405-2413.
    >> Share

  177. KAJIKAWA H, Hirata M, Haruna M, Ueyama A, et al
    Tumor-infiltrating ICOS(+) Effector Regulatory T-Cells in Oral Squamous Cell Carcinoma as a Promising Biomarker for Prognosis and 'Hot' Tumor.
    Anticancer Res. 2022;42:2383-2393.
    >> Share

  178. AOYAMA T, Ju M, Komori K, Tamagawa H, et al
    The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment.
    Anticancer Res. 2022;42:2711-2717.
    >> Share

  179. WONGPANUWICH W, Yodsanga S, Chaisuparat R, Amornphimoltham P, et al
    Association Between PD-L1 and Histatin1, 3 Expression in Advanced Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:2689-2699.
    >> Share

  180. KLIMAITE R, Kazokaite M, Kondrotiene A, Dauksiene D, et al
    Diagnostic Value of Circulating Cell-free DNA in Patients With Papillary Thyroid Cancer.
    Anticancer Res. 2022;42:2289-2299.
    >> Share

  181. HUANG TS, Lee JJ, Huang SY, Cheng SP, et al
    Regulation of Expression of Sterol Regulatory Element-binding Protein 1 in Thyroid Cancer Cells.
    Anticancer Res. 2022;42:2487-2493.
    >> Share

    April 2022
  182. TAKAKUSAGI Y, Kano K, Shima S, Tsuchida K, et al
    Clinical Outcomes of Radiotherapy in Elderly and Younger Patients With T4 Esophageal Cancer: A Retrospective Single-center Analysis.
    Anticancer Res. 2022;42:2095-2104.
    >> Share

  183. REMSCHMIDT B, Pau M, Gaessler J, Zemann W, et al
    Diabetes Mellitus and Oral Cancer: A Retrospective Study from Austria.
    Anticancer Res. 2022;42:1899-1903.
    >> Share

  184. MAYO ZS, Ilori EO, Matia B, Smile TD, et al
    Limited Toxicity of Hypofractionated Intensity Modulated Radiation Therapy for Head and Neck Cancer.
    Anticancer Res. 2022;42:1845-1849.
    >> Share

  185. TSUTSUMI S, Momiyama K, Ichinoe M, Kato T, et al
    The Significance of CD109 Expression in Oropharyngeal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:2061-2070.
    >> Share

    March 2022
  186. SUZUKI H, Yokoi M, Hagiwara S, Sasaki E, et al
    A Case of Salvage Maxillectomy for Recurrent Oral Cancer After Boron Neutron Capture Therapy During the COVID-19 Pandemic.
    Anticancer Res. 2022;42:1653-1657.
    >> Share

  187. ITO T, Okamoto I, Tokashiki K, Sato H, et al
    PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer.
    Anticancer Res. 2022;42:1547-1554.
    >> Share

  188. OKADA T, Fushimi C, Matsuki T, Okamoto I, et al
    Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:1607-1613.
    >> Share

  189. OHSAWA M, Hamai Y, Emi M, Ibuki Y, et al
    Neutrophil-to-Lymphocyte Ratio as a Predictor of Postoperative Recurrence and Prognosis in Oesophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:1499-1507.
    >> Share

  190. LIU A, Borges PM, Tay YS, Thompson LDR, et al
    Thyroid Follicular Cell-derived Carcinomas in a Background of Multiple Adenomatous Nodules Leading to a Diagnosis of PTEN Hamartoma Tumor Syndrome in an Adult Patient With a Novel RECQL4 Mutation.
    Anticancer Res. 2022;42:1481-1485.
    >> Share

  191. CLAUSEN S, Falk M, Oesterling F, Fehr A, et al
    Outcome of Ordinary Polymorphous Adenocarcinomas of the Salivary Glands in Comparison With Papillary and Cribriform Subtypes.
    Anticancer Res. 2022;42:1455-1463.
    >> Share

  192. MUSHA A, Kubo N, Kawamura H, Okano N, et al
    Carbon-ion Radiotherapy for Inoperable Head and Neck Bone and Soft-tissue Sarcoma: Prospective Observational Study.
    Anticancer Res. 2022;42:1439-1446.
    >> Share

  193. JIN MC, Qian ZJ, Megwalu UC
    Risk of Second Primary Malignancies After External Beam Radiotherapy for Thyroid Cancer.
    Anticancer Res. 2022;42:1359-1365.
    >> Share

    February 2022
  194. URAKAWA N, Kanaji S, Suzuki S, Sawada R, et al
    Prognostic and Clinicopathological Significance of Lymph Node Metastasis in the Esophagogastric Junction Adenocarcinoma.
    Anticancer Res. 2022;42:1051-1057.
    >> Share

  195. HASHIMOTO K, Yasumatsu R, Kuga R, Hongo T, et al
    Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma.
    Anticancer Res. 2022;42:981-989.
    >> Share

  196. DAVAKIS S, Charalabopoulos A, Kyros E, Sakarellos P, et al
    Minimally Invasive Transcervical Esophagectomy With Mediastinal Lymphadenectomy for Cancer. A Comparison With Standardized Techniques.
    Anticancer Res. 2022;42:675-680.
    >> Share

    January 2022
  197. RUDHART SA, Langen P, Thangavelu K, Gehrt F, et al
    Clinical Impact of CYFRA 21-1 a Marker for Treatment Failure in Patients With Oropharyngeal Cancer Treated by Radio(chemo)therapy.
    Anticancer Res. 2022;42:137-146.
    >> Share

  198. VEGH A, Banyai D, Ujpal M, Somogyi KS, et al
    Prevalence of Diabetes and Impaired Fasting Glycemia in Patients With Oral Cancer: A Retrospective Study in Hungary.
    Anticancer Res. 2022;42:109-113.
    >> Share

  199. ALSHARIF U, Steller D, Falougy M, Tharun L, et al
    The Benefit of Postoperative Radiotherapy and Extending Neck Dissection in pT1-2 Oral Squamous Cell Carcinoma With a Single Ipsilateral Cervical Lymph Node Metastasis (pN1).
    Anticancer Res. 2022;42:97-104.
    >> Share

  200. AL-JUMAYLI M, Choucair K, Al-Obaidi A, Park R, et al
    Pre-operative Carboplatin/Paclitaxel Versus 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer.
    Anticancer Res. 2022;42:59-66.
    >> Share

  201. KONISHI M, Takeuchi Y, Kubo K, Imano N, et al
    Reirradiation Using (198)Au Grain Brachytherapy for Recurrent Oral Cancer Cases Previously Treated by Definitive Radiotherapy.
    Anticancer Res. 2022;42:293-300.
    >> Share

  202. YOSHIDA T, Nishino T, Goto M, Inoue S, et al
    ypN0 in Patients With Definitive cN-positive Status After Preoperative Treatment Is a Prognostic Factor in Esophageal Cancer.
    Anticancer Res. 2022;42:195-203.
    >> Share

  203. KAMADA T, Ohdaira H, Ito E, Fuse Y, et al
    Preoperative Masseter Muscle Sarcopenia Predicts Mortality in Patients With Oesophageal Cancer.
    Anticancer Res. 2022;42:301-310.
    >> Share

  204. KONISHI M, Fujita M, Shimabukuro K, Wongratwanich P, et al
    Predictive Factors of Late Cervical Lymph Node Metastasis Using Intraoral Sonography in Patients With Tongue Cancer.
    Anticancer Res. 2022;42:287-292.
    >> Share

  205. TOYA R, Watakabe T, Murakami D, Matsuyama T, et al
    Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation.
    Anticancer Res. 2022;42:205-209.
    >> Share

    December 2021
  206. YOSHINO K, Okamoto I, Sato H, Okada T, et al
    Effect of Concomitant Lafutidine on Adjuvant S-1 for Head and Neck Cancer: A Comparative Study.
    Anticancer Res. 2021;41:6279-6285.
    >> Share

  207. HAMAI Y, Hihara J, Emi M, Ibuki Y, et al
    Prospective Randomized Trial of Early Postoperative Enteral and Total Parenteral Nutrition for Treating Esophageal Cancer.
    Anticancer Res. 2021;41:6237-6246.
    >> Share

  208. YOSHIMURA RI, Toda K, Watanabe H, Kaida A, et al
    Efficacy and Safety of Induction Chemotherapy and/or External Beam Radiotherapy Followed by Brachytherapy in Patients With Tongue Cancer.
    Anticancer Res. 2021;41:6259-6266.
    >> Share

  209. YUE CH, Chen CH, Pan YR, Chen YP, et al
    Cetyltrimethylammonium Bromide Disrupts Mesenchymal Characteristics of Human Tongue Squamous Cell Carcinoma SCC4 Cells Through Modulating Canonical TGF-beta/Smad/miR-181b/TIMP3 Signaling Pathway.
    Anticancer Res. 2021;41:6095-6104.
    >> Share

  210. NAKAMURA S, Mukudai Y, Chikuda J, Zhang M, et al
    Combinational Anti-tumor Effects of Chemicals from Paeonia lutea Leaf Extract in Oral Squamous Cell Carcinoma Cells.
    Anticancer Res. 2021;41:6077-6086.
    >> Share

  211. HARADA K, Ferdous T, Mishima K
    Efficacy of a Novel Oral Chemotherapeutic Agent, TAS-102, Against Human Oral Squamous Cell Carcinoma Cells.
    Anticancer Res. 2021;41:6039-6049.
    >> Share

    November 2021
  212. BABA D, Fushimi C, Hanyu K, Masubuchi T, et al
    Prognostic Factors of Potential Early Recurrence of Hypopharyngeal Carcinoma.
    Anticancer Res. 2021;41:5761-5766.
    >> Share

  213. WU J, Galvan KJ, Bogard RD, Peterson CE, et al
    DNA Double-strand Break Signaling Is a Therapeutic Target in Head and Neck Cancer.
    Anticancer Res. 2021;41:5393-5403.
    >> Share

  214. JOGIAT U, Grant C, Bedard ELR, Au K, et al
    Esophageal Adenocarcinoma Metastasizing to a Solitary Fibrous Tumor: An Unprecedented Case of Tumor-to-tumor Metastasis.
    Anticancer Res. 2021;41:5835-5838.
    >> Share

  215. NARUSE T, Yanamoto S, Otsuru M, Yamakawa N, et al
    Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:5785-5791.
    >> Share

  216. NA YM, Cho JS, Park MH
    Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
    Anticancer Res. 2021;41:5713-5721.
    >> Share

  217. ALSHARIF U, Hofmann M, Gebhard M, Tharun L, et al
    Double Positivity for HPV DNA/P16(INK4a) Does Not Influence Survival of Patients With Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:5557-5568.
    >> Share

  218. CIERPIKOWSKI P, Lis-Nawara A, Bar J
    SHH Expression Is Significantly Associated With Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:5405-5413.
    >> Share

    October 2021
  219. HUANG YH, Hung YS, Lai CC, Ho MM, et al
    Impact of Frailty on Treatment Outcome in Patients With Locally Advanced Esophageal Cancer Undergoing Concurrent Chemoradiotherapy.
    Anticancer Res. 2021;41:5213-5222.
    >> Share

  220. RADES D, Kopelke S, Soror T, Bartscht T, et al
    Risk Factors for Sleep Disturbances in Patients Scheduled for Radiotherapy of Head-and-Neck Cancer.
    Anticancer Res. 2021;41:5065-5069.
    >> Share

  221. IMAIZUMI T, Matsuda K, Tanaka K, Kondo H, et al
    Detection of Endogenous DNA Double-strand Breaks in Oral Squamous Epithelial Lesions by P53-binding Protein 1.
    Anticancer Res. 2021;41:4771-4779.
    >> Share

  222. EISMANN J, Elsayad K, Rolf D, Sarif I, et al
    Intensity-modulated Radiotherapy in Patients With Aggressive Extranodal Non-Hodgkin Lymphoma of the Head and Neck.
    Anticancer Res. 2021;41:5131-5135.
    >> Share

  223. LANDSTROM F, Aspenblad E, Reizenstein J, Kristiansson S, et al
    The Value of Post-treatment Surveillance for Detection of Loco-regional Recurrences in Oral Tongue Cancer.
    Anticancer Res. 2021;41:5059-5063.
    >> Share

  224. DOMB C, Smile TD, Reddy C, Woody NM, et al
    Updated Outcomes of Split Course Radiotherapy in Elderly or Infirm Patients With Advanced Cancers of the Head and Neck.
    Anticancer Res. 2021;41:4995-5000.
    >> Share

    September 2021
  225. SAKAI M, Sohda M, Uchida S, Yamaguchi A, et al
    Fibrin/fibrinogen Degradation Products Are Associated With Tumor Stage and Prognosis in Patients Undergoing Resection of Esophageal Cancer.
    Anticancer Res. 2021;41:4523-4527.
    >> Share

  226. KAWASAKI M, Sakabe T, Kodani I, Umekita Y, et al
    Cytoplasmic-only Expression of Maspin Predicts Poor Prognosis in Patients With Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:4563-4570.
    >> Share

  227. KOIKE K, Nishiyama K, Dehari H, Ogi K, et al
    Prognostic Value of CD45Ro(+) T-Cell Expression in Patients With Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:4515-4522.
    >> Share

    August 2021
  228. AGAWA K, Yamashita K, Nakagawa A, Yamada K, et al
    Simple Cancer Stem Cell Markers Predict Neoadjuvant Chemotherapy Resistance of Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:4117-4126.
    >> Share

  229. TOKASHIKI K, Okamoto I, Okada T, Sato H, et al
    Postoperative Complications of Jejunal and Skin Valve Reconstruction in Free Reconstructive Surgery for Hypopharyngeal Carcinoma.
    Anticancer Res. 2021;41:4033-4038.
    >> Share

  230. LANDSTROM F, Kristiansson S, Reizenstein J
    The Role of Electrochemotherapy in Curative Treatment of Head and Neck Cancer and Advanced Skin Cancer: A Need for New Treatment Protocols?
    Anticancer Res. 2021;41:3977-3982.
    >> Share

  231. YAMASHITA K, Miyazaki Y, Nakatani D, Masuike Y, et al
    OSK-0028 in Patients With Esophageal Cancer Undergoing Esophagectomy: A Double-blind, Randomised Controlled Trial.
    Anticancer Res. 2021;41:3875-3884.
    >> Share

  232. DE OLIVEIRA NETO CP, Brito HO, DA Costa RMG, Brito LMO, et al
    Is There a Role for Sex Hormone Receptors in Head-and-neck Cancer? Links with HPV Infection and Prognosis.
    Anticancer Res. 2021;41:3707-3716.
    >> Share

  233. SAKAI M, Sohda M, Uchida S, Yamaguchi A, et al
    Combining Preoperative Immunoinflammatory Scores and (18)F-Fluorodeoxyglucose Positron-emission Tomography Predicts Beneficiaries of Salvage Esophagectomy.
    Anticancer Res. 2021;41:4005-4011.
    >> Share

  234. WU TK, Ou YC, Chen YP, Huang FM, et al
    Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway.
    Anticancer Res. 2021;41:3789-3799.
    >> Share

    July 2021
  235. CAO C, Poti SM, Ledgerwood LG, Lai J, et al
    Mixed HPV-related Neuroendocrine Carcinoma and HPV-related Squamous Cell Carcinoma of the Base of Tongue in a Patient With Incidental Identification of Synchronous Metastatic Papillary Thyroid Carcinoma.
    Anticancer Res. 2021;41:3639-3642.
    >> Share

  236. LANDSTROM F, Kristiansson S, Appelros P
    Neurological Complications After Electrochemotherapy Treatment in the Head and Neck Area.
    Anticancer Res. 2021;41:3519-3522.
    >> Share

  237. KNITTER S, Andreou A, Hofmann T, Chopra S, et al
    Minimally Invasive Versus Open Ivor-Lewis Esophagectomy for Esophageal Cancer or Cancer of the Gastroesophageal Junction: Comparison of Postoperative Outcomes and Long-term Survival Using Propensity Score Matching Analysis.
    Anticancer Res. 2021;41:3499-3510.
    >> Share

  238. LUNDIN E, Reizenstein J, Landstrom F, Bergqvist M, et al
    Radiotherapy as Elective Treatment of the Node-negative Neck in Oral Squamous Cell Cancer.
    Anticancer Res. 2021;41:3489-3498.
    >> Share

  239. FUJITA J, Nakajima M, Muroi H, Kikuchi M, et al
    The Prognostic Significance of Plakophilin-1 Expression in Esophageal Cancer.
    Anticancer Res. 2021;41:3401-3407.
    >> Share

  240. KII T, Sakuma K, Tanaka A
    PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:3363-3370.
    >> Share

  241. HYAKUSOKU H, Sawakuma K, Sano D, Takahashi H, et al
    FosL1 Regulates Regional Metastasis of Head and Neck Squamous Cell Carcinoma by Promoting Cell Migration, Invasion, and Proliferation.
    Anticancer Res. 2021;41:3317-3326.
    >> Share

    June 2021
  242. STAACKMANN C, Ribbat-Idel J, Perner S, Idel C, et al
    Palliative Local Radiotherapy for Advanced Squamous Cell Carcinoma of the Head-and-Neck: Prognostic Factors of Survival.
    Anticancer Res. 2021;41:3205-3210.
    >> Share

  243. HAMAI Y, Emi M, Ibuki Y, Kurokawa T, et al
    Comparison of Open and Thoracoscopic Esophagectomy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy.
    Anticancer Res. 2021;41:3011-3021.
    >> Share

  244. KYRODIMOS E, Chrysovergis A, Mastronikolis N, Tsiambas E, et al
    Impact of Topoisomerases Complex Deregulation on Head and Neck Carcinoma Genomic Instability.
    Anticancer Res. 2021;41:2773-2779.
    >> Share

  245. RADES D, Staackmann C, Ribbat-Idel J, Perner S, et al
    A New Survival Score for Patients Scheduled for Palliative Irradiation of Locally Advanced Carcinoma of the Head-and-Neck.
    Anticancer Res. 2021;41:3055-3058.
    >> Share

  246. SARMA D, Karna R, Nasrullah A, Zhang Q, et al
    Primary Esophageal Small Cell Carcinoma Masquerading as Non-Hodgkin Lymphoma in a Young Patient.
    Anticancer Res. 2021;41:3023-3027.
    >> Share

  247. OKUHATA K, Monzen H, Tamura M, Matsumoto K, et al
    Plan Complexity and Delivery Accuracy of Knowledge-based Volumetric Modulated Arc Therapy Plans with Single Optimization for Oropharyngeal Cancer.
    Anticancer Res. 2021;41:2925-2931.
    >> Share

    May 2021
  248. RADES D, Staackmann C, Schild SE
    Karnofsky Performance Score - An Independent Prognostic Factor of Survival After Palliative Irradiation for Sino-nasal Cancer.
    Anticancer Res. 2021;41:2495-2499.
    >> Share

  249. HAAG A, Huffman D, Peterson C, Shankar K, et al
    Cutaneous Lesion of the Nose as Initial Presentation of Esophageal Adenocarcinoma.
    Anticancer Res. 2021;41:2485-2488.
    >> Share

  250. IWASAKI T, Onda T, Honda H, Hayashi K, et al
    Over-expression of PDE5 in Oral Squamous Cell Carcinoma - Effect of Sildenafil Citrate.
    Anticancer Res. 2021;41:2297-2306.
    >> Share

    April 2021
  251. YU WN, Lin HF, Lee YI, Shia WC, et al
    PBK Expression Is Associated With Prognosis of Patients With Oral Squamous Cell Carcinoma Treated With Radiotherapy: A Retrospective Study.
    Anticancer Res. 2021;41:2177-2182.
    >> Share

  252. SAKAI M, Sohda M, Saito H, Nakazawa N, et al
    Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-RT) vs. Cisplatin and 5-Fluorouracil (CF-RT) for Patients With Unresectable Locally Advanced Esophageal Cancer in a Real-world Clinical Setting.
    Anticancer Res. 2021;41:2141-2145.
    >> Share

  253. FRIEDRICH RE, Scheuer HT, Zustin J, Luebke AM, et al
    Microdont Developing Outside the Alveolar Process and Within Oral Diffuse and Plexiform Neurofibroma in Neurofibromatosis Type 1.
    Anticancer Res. 2021;41:2083-2092.
    >> Share

  254. SUZUKI M, Takenaka Y, Kishikawa T, Yamamoto Y, et al
    Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer.
    Anticancer Res. 2021;41:2045-2051.
    >> Share

  255. TAKAKUSAGI Y, Kusunoki T, Kano K, Anno W, et al
    Dosimetric Comparison of Radiation Therapy Using Hybrid-VMAT Technique for Stage I Esophageal Cancer.
    Anticancer Res. 2021;41:1951-1958.
    >> Share

  256. FUKUDA M, Ogasawara Y, Hayashi H, Okuyama A, et al
    Down-regulation of Glutathione Peroxidase 4 in Oral Cancer Inhibits Tumor Growth Through SREBP1 Signaling.
    Anticancer Res. 2021;41:1785-1792.
    >> Share

  257. PAWLICZAK J, Kolb M, Bauer M, Gminski R, et al
    Micronucleus Formation in Primary Oropharyngeal Epithelial Cells Reveals Mutagenicity of Cement Dusts.
    Anticancer Res. 2021;41:1849-1858.
    >> Share

  258. HOTTA H, Hamamura K, Shibuya H, Ohmi Y, et al
    Lewis y Expressed in Oral Squamous Cell Carcinoma Attenuates Malignant Properties via Down-regulation of EGF Signaling.
    Anticancer Res. 2021;41:1821-1830.
    >> Share

  259. OGO A, Miyake S, Kubota H, Higashida M, et al
    The Mechanism of the Synergistic Anticancer Effect of CDDP and EPA in the TE1 Cell Line.
    Anticancer Res. 2021;41:1771-1778.
    >> Share

  260. KOERDT S, Raguse JD, Neumann F, Beck-Broichsitter B, et al
    Value of Panendoscopy in the Identification of Synchronous Malignancies in Patients Suffering from Oral Squamous Cell Carcinoma Without Clinical Signs of a Second Primary Tumor.
    Anticancer Res. 2021;41:2039-2044.
    >> Share

    March 2021
  261. FUKUDA N, Toda K, Ohmoto A, Wang X, et al
    Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Anticancer Res. 2021;41:1683-1691.
    >> Share

  262. OWIN N, Elsayad K, Rolf D, Haverkamp U, et al
    Radiotherapy as Part of Treatment Strategies in Nasal Cavity and Paranasal Sinus Malignancies.
    Anticancer Res. 2021;41:1587-1592.
    >> Share

  263. KURIYAMA K, Sohda M, Watanabe T, Saito H, et al
    Resistance to Preoperative Oral Care Is Associated With Postoperative Pneumonia After Oesophageal Cancer Surgery.
    Anticancer Res. 2021;41:1507-1514.
    >> Share

  264. FRANZEN AM, Windfuhr JP
    Tonsillectomy as a Prevention Strategy in the Light of Increasing Incidence of Oropharyngeal Cancer - a Research of Current Literature.
    Anticancer Res. 2021;41:1157-1161.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016